GetTopicDetailResponse(id=506e5682c1, topicName=Dapagliflozin, introduction=Dapagliflozin, content=null, image=null, comments=0, allHits=1176, url=https://h5.medsci.cn/topic?id=5682, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=1737, tagList=[TagDto(tagId=1737, tagName=Dapagliflozin)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2222624, encodeId=e87d222262463, content=<a href='/topic/show?id=506e5682c1' target=_blank style='color:#2F92EE;'>#Dapagliflozin#</a> <a href='/topic/show?id=fff21184032c' target=_blank style='color:#2F92EE;'>#自體顯性多囊腎病CKD患者#</a>, objectTitle=CKJ：Dapagliflozin在自體顯性多囊腎病CKD患者中的療效與安全性, objectType=article, longId=840723, objectId=adf7840e2310, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721282756373_92910.jpg, objectUrl=/article/show_article.do?id=adf7840e2310, replyNumber=0, likeNumber=88, createdTime=2024-08-27, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=adf7840e2310, moduleTitle=CKJ：Dapagliflozin在自體顯性多囊腎病CKD患者中的療效與安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=adf7840e2310)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188644, encodeId=3a2e218864469, content=<a href='/topic/show?id=851de10460f' target=_blank style='color:#2F92EE;'>#病理生理學(xué)#</a> <a href='/topic/show?id=506e5682c1' target=_blank style='color:#2F92EE;'>#Dapagliflozin#</a> <a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=0b2b111396b1' target=_blank style='color:#2F92EE;'>#GLP-1激動(dòng)劑索馬魯肽（Semaglutide）#</a>, objectTitle=Nature Metabolism：針對(duì)不同病理生理學(xué)的 2 型糖尿病患者的隨機(jī)開(kāi)放標(biāo)簽試驗(yàn)：semaglutide 和 dapagliflozin, objectType=article, longId=814186, objectId=9b30814186c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696890986365_4754896.jpeg, objectUrl=/article/show_article.do?id=9b30814186c7, replyNumber=0, likeNumber=80, createdTime=2024-02-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9b30814186c7, moduleTitle=Nature Metabolism：針對(duì)不同病理生理學(xué)的 2 型糖尿病患者的隨機(jī)開(kāi)放標(biāo)簽試驗(yàn)：semaglutide 和 dapagliflozin, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9b30814186c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
